No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 21 of the 40 quarters in the window, leaving 19 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:36:48.217Z. Latest historical point 2021-12-28. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Edesa Biotech, Inc. (EDSA) stock was $3.85 as of Oct 6, 2026, 10:33 AM EDT, down 1.53% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +52.4% · 3-year avg -3.9%/yr · 5-year avg -39.9%/yr
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate.
Biotechnology · Markham, ON
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2018-09-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Dec 11, 2026
66 days away
EPS Estimate
-0.58
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.60
vs Estimate
$-0.43
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1EDSA | $37.09M | $3.85 | -1.53% | +52.43% | -39.88% | -40.32% | N/A |
| 2DCGO | $36.48M | $0.37 | +1.18% | -71.09% | -48.40% | N/A | vs EDSA |
| 3ELTX | $36.04M | $1.89 | -1.56% | -82.46% | N/A | N/A | vs EDSA |
| 4ARAY | $35.90M | $0.30 | +0.03% | -82.00% | -39.94% | -25.77% | vs EDSA |
| 5ELUT | $35.42M | $0.80 | -2.47% | -6.61% | -33.96% | N/A | vs EDSA |
| 6IXHL | $38.82M | $3.25 | +1.09% | -77.63% | N/A | N/A | vs EDSA |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 3 analysts
Average Price Target
$16.33
+324.2% upside
Low
$9.00
Current
$3.85
High
$21.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.68 | $-0.58 | $-0.48 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.21 | $-1.99 | $-1.75 | 2 |
| FY 2027 | $-2.82 | $-2.07 | $-1.30 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $19.00M | $19.00M | $19.00M | 3 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
